GT Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 0.227 million compared to USD 5.44 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 5.1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.57 USD | +0.14% | +1.13% | -53.33% |
May. 21 | Top Midday Decliners | MT |
May. 21 | GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants | MT |
1st Jan change | Capi. | |
---|---|---|
-53.33% | 7.69M | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- GTBP Stock
- News GT Biopharma, Inc.
- GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023